Single Direct-to-tumor Drug-delivery Device Offers Hope for Treating Triple-negative Breast Cancer
Houston Methodist scientists have developed a nanodevice to deliver immunotherapy without side effects to treat triple-negative breast cancer. Inserted straight into a tumor, this nanofluidic seed makes it possible to deliver a one-time, sustained-release dose that would eliminate the need for patients to undergo several IV treatments over time.
Invented by Alessandro Grattoni, Ph.D., chairman of the Department of Nanomedicine at the Houston Methodist Research Institute, this tiny device is smaller than a grain of rice and, once inserted inside a tumor, can deliver the medication little by little, gradually releasing the drug from its reservoir.
“With this research we are trying to establish a novel strategy to deliver immunotherapy straight into a tumor instead of delivering it to the whole body of a patient,” Grattoni said. “And we’re trying to understand whether delivering it this way would actually be more effective and have less side effects as compared to conventional immunotherapy, which today is given to the entire body of the patient.”
Grattoni and team are not alone in studying ways to administer immunotherapeutics intratumorally. What distinguishes his approach from others is the use of the implantable nanodevice that can be placed inside the tumor very accurately, with just one, simple procedure and with the ability to sustain the delivery of the immunotherapy over a prolonged period of time.
“Timing of the release may be extremely important,” said E. Brian Butler, M.D., chair of the Department of Radiation Oncology at Houston Methodist and Grattoni’s co-senior author on a recent paper in the Journal of Controlled Release. “These immunotherapy payloads Dr. Grattoni created come in a little metal device with nanochannels that release the medication at a constant rate in a controlled way.”
Grattoni, who also is the corresponding author, says that by providing sustained doses, their implant maintains an active level of the drug for extended periods of time. This would reduce the need for continual clinic visits, which are usually required for immunotherapy and other cancer treatments.
By contrast, most other methods currently under preclinical and clinical trials require multiple injections into the tumor and, in many instances, necessitate repeated invasive procedures to access it. Additionally, injecting drugs straight into a tumor as a single dose may not be very effective, as only a part of it will stay, with the rest being rapidly eliminated due to the high-pressure nature of a tumor’s microenvironment. Grattoni’s intratumoral sustained-delivery method prevents this from happening.
“We’re in the middle of an exciting time in medicine, because if we can get it to work, you decrease the toxicities to the patient,” Butler said. “This offers the opportunity of treating locally and getting the systemic response without all the side effects.”
Grattoni likens their device to an hourglass.
“Our implant releases the drug in a constant manner until the entire amount is completely gone from the reservoir,” Grattoni said. “Since it can deliver the immunotherapy by itself for weeks to potentially months, we would only need to place the device inside the tumor once and then the drug would be released autonomously for that long period of time.”
While this platform technology can be applied to many different types of cancer, they chose to work on triple-negative breast cancer, since there’s not currently a good therapeutic approach for treating patients that are affected by the disease.
Breast cancer is traditionally not considered immunogenic, which means it may not respond well to immunotherapy, but triple-negative breast cancer (TNBC) is more immunogenic than other breast cancer subtypes. This is another reason why the researchers chose to focus on it. They are trying to make TNBC more responsive to the treatment with their implant.
“In this study we demonstrated in mice that our intratumoral delivery of immunotherapy was equally effective compared to systemic immunotherapy treatment,” Grattoni said. “The difference was that the systemic immunotherapy showed significant side effects, while our device delivered the same effective treatment without side effects. We were, in fact, able to completely eliminate side effects, which was very surprising to us.”
The next phase of their research, also in mice, will be to combine the device with radiation therapy to see if this approach can improve on the effectiveness currently achieved through systemic delivery of immunotherapy and not just equal it.
“Using Dr. Grattoni’s nanodevice in conjunction with our clinic, we hope to create a very robust immunological response, by putting the immunotherapy directly into the tumor, which is where all the information is,” Butler said. “This will allow us to possibly harness the full power of a person’s immune system to destroy the cancer, offering the opportunity to get the systemic response, while treating locally, without all the side effects.”
In addition to the sustained release system, Grattoni’s nanodevice serves as a fiducial marker to facilitate precise delivery for image-guided radiation. Their hope is that in combination with radiation therapy, this device would not only provide an alternative, but also help improve upon current immunotherapeutic approaches.
“We are hoping to go to patients within three years,” Grattoni said. “We would definitely improve on what is out there currently and what other groups are already studying.”
The Latest on: Immunotherapy
via Google News
The Latest on: Immunotherapy
- Cancer Immunotherapy Market Research Report: CAGR Status, Industry Growth, Trends, Analysis and Forecasts to 2025on January 20, 2021 at 8:15 pm
Selbyville, Delaware According to Market Study Report, Cancer Immunotherapy Market provides a comprehensive analysis of the Cancer Immunotherapy market segments, including their dynamics, size, growth ...
- Immunotherapy biotech NexImmune files for an $86 million IPOon January 19, 2021 at 1:42 pm
N exImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering. NexImmune is developing a novel ...
- Study predicts good passive immunotherapy donors to combat COVID-19on January 19, 2021 at 10:09 am
A US-based research team determine good candidates for convalescent plasma donations in promoting passive immunity among severely-ill COVID-19 patients.
- Unexpectedly, Immunotherapy Response Linked to Low TMB in rGMBon January 19, 2021 at 8:55 am
In contrast to what has been seen in other tumor types, recurrent glioblastoma (rGMB) appears to respond better to immunotherapy when tumor mutational burden (TMB) is low.
- Therapeutic Solutions International Reports Successful Treatment of Breast Cancer using StemVacs™ Cellular Immunotherapyon January 19, 2021 at 8:31 am
Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported positive animal data in the 4T1 breast cancer model using its clinically tested StemVacs™ cellular immunotherapy. In a series ...
- Immunotherapy Veteran Robert Knight, MD, Joins NexImmune as Chief Medical Officeron January 18, 2021 at 9:54 pm
NexImmune today announced the appointment of Dr. Robert (Bob) Knight as Chief Medical Officer (CMO). Dr. Knight is a seasoned executive with extensive experience leading early- and late-stage ...
- New study identifies opposite roles of sugars and fat on cellular immunotherapy of canceron January 17, 2021 at 9:00 pm
The team led by Bruno Silva Santos, Principal Investigator iMM, discovered that the functions of a subtype of white blood cells - gamma delta T cells - are regulated by metabolic resources, namely ...
- Study may help develop more effective personalized immunotherapy for cancer patientson January 14, 2021 at 10:01 pm
New research from CU Cancer Center member Jing Hong Wang, MD, PhD, and recent University of Colorado Immunology program graduate Rachel Woolaver, PhD, may help researchers develop more effective ...
- New humanized mouse model provides insight into immunotherapy resistanceon January 12, 2021 at 10:58 am
Scientists have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma. It has revealed a central role for ...
via Bing News